Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.

doi:10.1016/j.jtho.2016.03.006

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jul 2016

La Monica Silvia, Madeddu Denise, Tiseo Marcello, Vivo Valentina, Galetti Maricla, Cretella Daniele, Bonelli Mara, Fumarola Claudia, Cavazzoni Andrea, Falco Angela, Gervasi Andrea, Lagrasta Costanza Annamaria, Naldi Nadia, Barocelli Elisabetta, Ardizzoni Andrea, Quaini Federico, Petronini Pier Giorgio, Alfieri Roberta

Abstract excerpt

INTRODUCTION: Development of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors is a clinical issue in patients with epidermal growth factor receptor gene (EGFR)-mutated non-small cell lung cancer (NSCLC). The aim of this study was to investigate the potential of combining gefitinib and pemetrexed in preventing the acquisition of resistance to EGFR tyrosine kinase inhibitors in NSCLC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Drug Resistance, Neoplasm

Share to Epithelial-Mesenchymal Transition

Share to Gefitinib

Share to Pemetrexed

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Open in PubMed

Identifiers

PMID: 27006151
DOI: 10.1016/j.jtho.2016.03.006

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.PMID 27006151Read ↗

Concurrent Pemetrexed With EGFR-TKI Slows the Accumulation of De Novo Mutations During In Vitro Exposure.Semantic proximity Read ↗

Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3.Semantic proximity Read ↗

A Novel Molecular Target in EGFR-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed.Semantic proximity Read ↗

EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models.Semantic proximity Read ↗

Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.Semantic proximity Read ↗

Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.Semantic proximity Read ↗

Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.Semantic proximity Read ↗

Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.Semantic proximity Read ↗

Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.Semantic proximity Read ↗

Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.Semantic proximity Read ↗

Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.Semantic proximity Read ↗

Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.